Veracyte, Inc. (NASDAQ:VCYT) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET
Company Participants
Shayla Gorman - Director of Investor Relations
Marc Stapley - Chief Executive Officer
Rebecca Chambers - Executive Vice President and Chief Financial Officer
Tina Nova - President, U.S. CLIA Business
Conference Call Participants
Jacob Johnson - Stephens
Griffin Soriano - William Blair
Mike Matson - Needham & Company
Hugo Leo - Morgan Stanley
David Hein - Goldman Sachs
Operator
Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2022 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. Please be advised at today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Shayla Gorman, Director of Investor Relations. Please go ahead.
Shayla Gorman
Good afternoon, everyone. And thanks for joining us today for a discussion of our third quarter 2022 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer; Rebecca Chambers, our Chief Financial Officer; Dr. Tina Nova, President of our U.S. CLIA Business; and Dr. Giulia Kennedy, Global Chief Scientific Officer and Chief Medical Officer.
Veracyte issued a press release earlier this afternoon detailing our third quarter 2022 financial results. This news release, along with a business and financial presentation, is available in the Investor Relations section of our website at Veracyte.com.
Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under the applicable securities laws. Forward-looking statements are subject to risks and uncertainties and the company can give no assurance they will prove to be correct. Further we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte filed with the Securities and Exchange Commission, including Veracyte's most recent Forms 10-Q and 10-K.
In addition, this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures are included in today's earnings release, accessible from the IR section of Veracyte's website.
I will now turn the call over to Marc Stapley, Veracyte, CEO.
Marc Stapley
Thanks, Shayla, and thanks, everyone, for joining us today. Our first quarter was incredibly strong in all respects and we delivered growth of 25% year-over-year achieving revenue of %75.6 million. With outstanding execution by our team, we continue to realize the potential of our highly valuable CLIA test, while also advancing our long-term growth opportunities and strategic vision.